Clinical trials: Peripheral Nervous System Disorders
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm
Individual Patient Compassionate Use of Mirdametinib
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
- Conditions
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases
- Trial name
- NCT05028166
- Testing
- Mirdametinib (MEK Inhibitor)
- Where
- 2 sites in United States, Germany
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Neurofibromatosis 1, Plexiform Neurofibroma
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib.
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma, NF1
- Trial name
- NCT04954001
- Testing
- FCN-159
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 160 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Pain, Irritability
Implementation of the Pain and Irritability of Unknown Origin (PIUO) Pathway in Community Pediatric Practices
The Pain and Irritability of Unknown Origin (PIUO) Pathway is a clinical pathway that was developed to evaluate and manage unexplained pain and irritability for children with severe neurological impairments (SNI) who cannot…
- Conditions
- Pain, Irritability, Neuropathic Pain
- Trial name
- NCT06869928
- Testing
- PIUO Pathway
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Neoplasms, Adenomatous Polyposis Coli
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function.
- Conditions
- Neoplasms, Adenomatous Polyposis Coli, Neurofibroma, Plexiform, Myelodysplastic Syndromes
- Trial name
- NCT03027401
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00891722
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Children's Cancer and Leukaemia Group
Obstetrical Brachial Plexus Palsy
Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy
In children population with obstetrical brachial plexus palsy (OBPP), shoulder musculoskeletal deformity is the main cause of morbidity, with a loss of range of shoulder motion, pain and a reduction in social participation.
- Trial name
- POPB-TOX (NCT03198702)
- Testing
- Botulinum toxin type A injection
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Brest
Chronic Pain, Musculoskeletal Pain
Empowered Relief for Youth
The purpose of this pilot study is to examine the feasibility and preliminary efficacy of Empowered Relief for Youth with chronic pain (ER-Y).
- Conditions
- Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Neuropathic Pain
- Trial name
- ER-Y (NCT05998369)
- Testing
- Empowered Relief for Youth
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Stanford University
Neuroblastoma, Brain Tumor
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to investigate whether the prophylactic use of itraconazole is a better option than empirical use of itraconazole in the management (prevention and treatment) of fungal infection associated with…
- Conditions
- Neuroblastoma, Brain Tumor, Retinoblastoma, Wilms Tumor
- Trial name
- NCT00336531
- Testing
- itraconazole
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Leg Pain, Peripheral Nerve Discontinuities
Effect of Nerve Stimulation on Sciatic Nerve Injury Pediatric Patients
Brief Summary The goal of this study is to learn if Faradic Nerve Stimulation (FNS) can help children recover from a condition called Post-Injection Sciatic Nerve Injury (PISNI).
- Conditions
- Leg Pain, Peripheral Nerve Discontinuities, Muscle Weakness, Sciatic Nerve Compression
- Trial name
- PISNI (NCT06781060)
- Testing
- Faradic Nerve Stimulation Therapy+Standard Physiotherapy, Physiotherapy Standard Treatment with TENS machine therapy
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Azeem Hospital, Multan
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00792142
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Peroxisome Biogenesis Disorder, Zellweger Spectrum Disorder
Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)
The Peroxisome Biogenesis Disorders (PBD) are a group of inherited disorders due to defects in peroxisome assembly causing complex developmental and metabolic sequelae.
- Conditions
- Peroxisome Biogenesis Disorder, Zellweger Spectrum Disorder, RCDP - Rhizomelic Chondrodysplasia Punctata, D-Bifunctional Protein Deficiency
- Trial name
- NCT01668186
- Where
- Canada
- Volunteers
- 244 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Neuropathic Pain
Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)
The objective of this investigation is to evaluate the safety and efficacy of long term use with Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will…
- Trial name
- RAINBOW-L (NCT01279850)
- Testing
- Pregabalin (Lyrica) capsule
- Volunteers
- 891 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Charcot-Marie-Tooth Disease, Type IA
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. treatment with PXT3003 or placebo, are eligible to continue in the extension study CLN-PXT3003-03.
- Trial name
- PLEO-CMT-FU (NCT03023540)
- Testing
- PXT3003
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 187 people
- Sponsor
- Pharnext S.C.A.
Neurofibromatosis
Natural History Study of Patients With Neurofibromatosis Type 2
Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progression and neurological disease burden in NF2.
- Trial name
- NCT00598351
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Muscular Dystrophies, Muscle Myopathies
Genetic and Physical Study of Childhood Nerve and Muscle Disorders
Background: Some nerve and muscle disorders that start early in life (before age 25), like some forms of muscular dystrophy, can run in families. However, the genetic causes of these disorders are not known.
- Conditions
- Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies
- Trial name
- NCT01568658
- Where
- United States
- Volunteers
- 2,586 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Headache, Cervical Radiculopathy
Outcomes After Surgery for Degenerative Cervical Radiculopathy in Patients with Concurrent Headache
Surgery for degenerative cervical radiculopathy (DCR) is one of the most common causes of neck surgery. The typical surgical indication is radicular pain (arm pain) caused by nerve impingement.
- Trial name
- NCT06885216
- Testing
- Anterior cervical discectomy and fusion/ posterior decompression
- Volunteers
- 12,000 people
- Sponsor
- University Hospital of North Norway
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Neurofibromatosis Type 1, Pediatric Brain Tumor
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
This study will analyze DNA samples to determine associations between maternal and offspring genetic factors and pediatric brain tumor development in children with Neurofibromatosis Type 1.
- Trial name
- NCT01707836
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Washington University School of Medicine